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PKB/AktEukaryotic elongation factor 2 (eEF-2) and mammalian target of rapamycin (mTOR)–p70 ribosomal protein S6
kinase (p70S6K) signaling pathways control protein synthesis and are inhibited during myocardial ischemia. In-
tracellular acidosis and AMP-activated protein kinase (AMPK) activation, both occurring during ischemia, have
been proposed to participate in this inhibition. We evaluated the contribution of AMPKα2, the main cardiac
AMPK catalytic subunit isoform, in eEF2 andmTOR–p70S6K regulation using AMPKα2 KOmice. Hearts were per-
fused ex vivowith orwithout insulin, and then submitted or not to ischemia. Insulin pre-incubationwasnecessary
to activate mTOR–p70S6K and evaluate their subsequent inhibition by ischemia. Ischemia decreased insulin-
induced mTOR–p70S6K phosphorylation in WT and AMPKα2 KO mice to a similar extent. This AMPKα2-
independent p70S6K inhibition correlated well with the inhibition of PKB/Akt, located upstream of mTOR–
p70S6K and can be mimicked in cardiomyocytes by decreasing pH. By contrast, ischemia-induced inhibitory
phosphorylation of eEF-2 was drastically reduced in AMPKα2 KO mice. Interestingly, AMPKα2 also played a
role under normoxia. Its deletion increased the insulin-induced p70S6K stimulation. This p70S6K over-
stimulation was associated with a decrease in inhibitory phosphorylation of Raptor, an mTOR partner identiﬁed
as an AMPK target. In conclusion, AMPKα2 controls cardiac p70S6K under normoxia and regulates eEF-2 but
not the mTOR–p70S6K pathway during ischemia. This challenges the accepted notion that mTOR–p70S6K is
inhibited by myocardial ischemia mainly via an AMPK-dependent mechanism.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The regulation of protein synthesis involves the phosphorylation/
dephosphorylation of several translation factors and ribosomal pro-
teins [1]. Two pathways implicating eukaryotic elongation factor 2
(eEF2) and p70 ribosomal S6 protein kinase (p70S6K) are known to
play a central role in this process and to be tightly regulated. eEF2 is
required for peptide chain elongation and is controlled by the
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l rights reserved.kinase (eEF2K) [2,3]. eEF2K phosphorylates eEF2 at Thr56 inducing
its inactivation [2]. On the other hand, p70S6K phosphorylates ribosom-
al S6 protein (S6) which was proposed to be involved in the translation
of the 5′-TOPmRNAs that encode ribosomal proteins and elongation fac-
tors [1]. p70S6K is activated by different anabolic agents, including insu-
lin and the insulin-like growth factor-1 (IGF-1) via the protein kinase B
(PKB/Akt)-mammalian target of rapamycin (mTOR) pathway [4]. mTOR
is a protein kinase that interacts with two regulatory proteins, Raptor
and mLST8, to form a complex called mTOR complex 1 (mTORC1) [5].
Insulin- or IGF-mediated PKB/Akt activates mTORC1 via different com-
plexmolecularmechanisms that involve, among others, the inactivation
of tuberous sclerosis complex 2 (TSC2) [4,6–8]. In addition to p70S6K,
mTORC1 also regulates a second substrate called eukaryotic initiation
factor-4E (eIF-4E) binding protein-1 (4E-BP1)[9]. Phosphorylation of
4E-BP1 by mTORC1 relieves its inhibitory action on eIF-4E, which can
then bind the mRNA cap for translation initiation.
We [10,11] and others [12,13] have previously shown that both eEF2
and p70S6K pathways are inhibited duringmyocardial ischemia, partic-
ipating in the inhibition of energy-demanding protein synthesis, a com-
mon feature of this condition. However, two different mechanisms
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[11,14]. This acidosis inhibits the tyrosine kinase activity of the insulin re-
ceptor impairing downstream insulin signaling including PKB/Akt and
p70S6K [11]. Second, myocardial ischemia promotes activation of the
AMP-activated protein kinase (AMPK) [15]. AMPK is a Ser/Thr protein ki-
nase that acts as a cellular energy sensor activating ATP-generating cata-
bolic pathways and inhibiting ATP-consuming biosynthetic pathways
[16–19]. As reported by numerous reports [10,12,20–27], AMPK partici-
pates in the control of protein synthesis. For instance, AMPK inactivates
eEF2 via the phosphorylation-induced activation of eEF2K [22,24]. Ini-
tially described in the hepatocytes [23], AMPK also inhibits the mTOR-
p70S6K pathwaymainly via twomechanisms. Firstly, AMPK phosphory-
lates the mTOR binding partner Raptor (for Regulatory associated
protein of mTOR) on Ser792, inducing mTOR inhibition [28,29]. Second-
ly, AMPK can phosphorylate and activate TSC2, which leads to mTOR-
p70S6K inactivation [30]. Concerning the heart, we [31] and others
[25,27] have previously shown that pharmacological activation of
AMPK was found to inhibit both p70S6K and eEF2. However, the level
of implication of AMPK in the regulation of these signaling pathways
under myocardial ischemia, where acidosis also occurs and could play a
major role, has not yet been investigated.
In the present study, we evaluated the role of AMPK in the
ischemia-mediated inhibition of both eEF2 and p70S6K in AMPKα2
knockout (KO) mice. AMPKα2 is the predominant catalytic subunit
isoform in the heart. AMPKα2 KO mice have already been extensively
studied [32–36]. The mice are glucose intolerant and characterized by
a defect in the regulation of several AMPK targets including cardiac
acetyl-coA carboxylase [33] and display impaired glucose uptake in
ischemic heart [34].
2. Materials and methods
This study was approved by the Animal Research Committee of
the Université catholique de Louvain and conformed to the American
Heart Association Guidelines for Use of Animals in Research.
2.1. Materials
Ketamin was obtained from Pﬁzer and Xylazin from Bayer. Unless
otherwise stated, the source of all other materials is as cited previously
[11,37].
2.2. Perfusion protocols
Mice were anesthetized with Ketamin/Xylazin (0.1/0.01 mg/g body
weight, ip). Hearts were perfused retrogradely at 37 °C at a constant
pressure of 75 mm Hg with a Krebs–Henseleit buffer containing
1.5 mM CaCl2, 11 mM glucose and 1.1 mM mannitol in equilibrium
with a 95% O2/5% CO2 gas phase [33]. After an equilibration period of
15 min, the heartswere submitted to 10 min of normoxia or no-ﬂow is-
chemia. When indicated, hearts were perfused with 100 nM insulin
5 min before starting the ischemic (or normoxic) episode. At the end
of the procedure, the hearts were immediately clamped with tongs
pre-cooled in liquid nitrogen and stored at −80 °C. Frozen hearts
were homogenized (Ultra-Turrax) at 0 °C in 10 vol (v/w) of homogeni-
zation buffer as previously described [38]. After centrifugation
(10,000 g, 30 min), the supernatants were used for further analysis.
2.3. Preparation of isolated cardiomyocytes
Adult rat cardiomyocytes were isolated as described [37]. Adult
mouse cardiomyocytes were isolated following a similar protocol.
Brieﬂy, mouse heart was perfused with a Ca2+-free Krebs–Henseleit
buffer containing 5,6 mM glucose, 5 mM taurine, 20 mM NaHCO3
(pH 7.5) and 10 mM 2,3-Butanedione 2-monoxime with a ﬂow rate
of 2.5 ml/min. Cardiomyocytes isolation was obtained by adding0.025 mM Ca2+ and 0.06 mg/ml Liberase Blenzyme 1 (Roche Diag-
nostics) to the perfusate. 20 min after perfusion with the enzyme,
the heart was removed from the apparatus and chopped into small
fragments. Cells were then dissociated mechanically and Ca2+ was
progressively reintroduced during different washes to reach a ﬁnal
concentration of 1 mM. The pellet containing the cardiomyocytes was
then ﬁltered before resuspension. Cardiomyocytes were resuspended
(20 or 2 mgwet weight/mL for rat and mouse, respectively) in a medi-
um containing 95 mM NaCl, 25 mM PIPES, 25 mM MES, 4.7 mM KCl,
1.25 mM MgSO4, 1.2 mM H2PO4, 1 mM CaCl2, 10 mM glucose and
1XMEM Amino Acids Solution (Life Technologies, Inc), at the indicated
pH. Cardiomyocytes were preincubated for 20 min, then incubated
with or without 100 nM insulin for 5 min and ﬁnally centrifuged
(10,000 g, 5 s). The cell pelletswere frozen in liquid nitrogen and stored
at−80 °C. Frozen pellets were lysed as previously described [37] and
used for further analysis.
2.4. Enzyme assays and immunoblot analysis
PKB/Akt and p70S6K activitieswere assayed after immunoprecipita-
tion with an anti-PKB/Akt (from Cell Signaling) and an anti-p70S6K an-
tibody (from Santa Cruz), respectively [11,39]. α1- and α2-speciﬁc
AMPK activities were measured after immunoprecipitation with anti-
AMPKα1 and anti-AMPKα2 antibodies (kindly provided by G. Hardie,
Dundee, Scotland) as described [38]. One unit of AMPK activity corre-
sponds to 1 nmol of product formed per minute under the assay condi-
tions. The phosphorylation state of p70S6K, mTOR, Raptor, PKB/Akt, S6
and eEF2 was assessed by immunoblotting using anti-phospho-Thr389
p70S6K, anti-phospho-Ser2448 mTOR, anti-phospho-Ser792 Raptor,
anti-phospho-Thr473 PKB/Akt, anti-phospho-Ser235/236 S6 and anti-
phospho-Thr56 eEF2 antibodies (all from Cell Signaling), respectively.
The total amount of p70S6K, mTOR, Raptor, PKB/Akt, S6 and eEF2 was
also assessed by immunoblotting using anti-p70S6K (Santa Cruz), anti-
mTOR, anti-Raptor, anti-PKB/Akt, anti-S6 and anti-eEF2 (all from Cell
Signaling) antibodies, respectively. The association of 4E-BP1 with
eIF-4E was measured by eIF-4E pull-down from heart extracts on
methyl-7-GTP Sepharose 4B beads (Amersham Pharmacia Biotech).
Samples (250 μg of protein extracts) were incubated with 40 μl of
methyl-7-GTP Sepharose resin for 1 h at 4 °C. The resin was washed
three timeswith ice-cold lysis buffer [11] and boundproteinswere elut-
ed directly into sample buffer for SDS-PAGE and immunoblot analysis.
The amount of co-eluted eIF-4E and 4E-BP1was detected by incubating
membranes with both anti-eIF-4E (Cell Signaling) and anti-4E-BP1
(Calbiochem) antibodies. Band intensities were quantiﬁed by scanning
and processing with the program Image J (1.33 for Mac OSX). Band in-
tensities obtained with anti-phospho antibodies were normalized rela-
tive to those of a loading control (anti-eEF2 or anti-PKB/Akt) on the
same gel after stripping and to those of the respective anti-total anti-
body on another gel. Each immunoblot was delimited by a solid rectan-
gle. When present, vertical dashed lines denote that samples were run
on the same gel but are not contiguous.
2.5. Statistical analysis
The results are expressed as means ± SEM. Statistical signiﬁcance
was calculated using a one-way analysis of variance (ANOVA) using
the Bonferroni for post-hoc test (for multiple comparisons) and an
unpaired Student's t-test (for comparisons of two groups).
3. Results
3.1. Effect of ischemia on eEF2 phosphorylation
We previously showed that myocardial ischemia induced a paral-
lel increase in AMPK activity and eEF2 Thr56 phosphorylation in iso-
lated perfused rat hearts [10], thus suggesting a role for AMPK in the
Table 1
AMPK activity in non-stimulated mouse hearts.
AMPK activity
(mU/mg of protein)
Heart
treatment
WT AMPKα2 KO P⁎
AMPKα1 Normoxia 8.3 ± 1.9 9.2 ± 1.3 n.s.
Ischemia 39.0 ± 4.7 46.6 ± 4.0 n.s.
AMPKα2 Normoxia 8.7 ± 1.8 0.5 ± 0.2 p b 0.01
Ischemia 56.3 ± 5.9 0.6 ± 0.3 p b 0.01
The values are the means ± S.E.M. of at least 7 hearts.
⁎ Unpaired T-test.
Table 2
AMPK activity in insulin-stimulated mouse hearts.
AMPK activity
(mU/mg of protein)
Heart
treatment
WT AMPKα2 KO P⁎
AMPKα1 Normoxia 3.2 ± 2.5 8.5 ± 3.1 n.s.
Ischemia 31.8 ± 3.2 41.6 ± 9.6 n.s.
AMPKα2 Normoxia 5.5 ± 2.2 0.6 ± 0.3 p b 0.01
Ischemia 47.1 ± 12.7 0.1 ± 0.5 p b 0.01
The values are the means ± S.E.M. of at least 3 hearts.
⁎ Unpaired T-test.
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substantiate the possible participation of AMPK in the control of eEF2
phosphorylation, we submitted isolated perfused hearts from WT and
AMPKα2 KO mice to either normoxia or 10 min no-ﬂow ischemia. As
previously shown [33], ischemia markedly increased both AMPKα1
(5-fold, p b 0.01) and AMPKα2 (6-fold, p b 0.01) activity in WT hearts
(Table 1). As expected, ischemia increased AMPKα1 activity (5-fold,
p b 0.01) but AMPKα2 activity remained undetectable in AMPKα2 KO
hearts. Under normoxic conditions, no eEF2 Thr56 phosphorylation
was detectable in either WT or AMPKα2 KO mice (Fig. 1). The absence
of eEF2 phosphorylation during normoxia implies that eEF2 is fully active
in this condition. As demonstrated previously [10], no-ﬂow ischemia led
to eEF2 phosphorylation in WT hearts. This ischemia-dependent eEF2
phosphorylation was signiﬁcantly reduced in AMPKα2 KO mice. As
shown in the immunoblot of Fig. 1, this decrease in eEF2 phosphorylation
in AMPKα2 KOmice cannot be explained by a decrease in total eEF2 pro-
tein content.
3.2. Effects of ischemia on PKB/Akt and p70S6K
Inhibition of the PKB/Akt-p70S6K pathway cannot be demonstrated
in isolated perfused hearts under basal conditions, because this path-
way is not sufﬁciently active [10,11]. Therefore, hearts were pretreatedNormoxia
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chemic episode. Moreover, we intentionally used doses of insulin that
were high enough to maximally stimulate this pathway in order to
readily detect inhibitory effects of ischemia. Table 2 shows AMPK acti-
vation under these conditions. Comparable to the data obtained in the
absence of insulin, ischemia activated both AMPKα1 and AMPKα2 in
WT hearts. As expected, in AMPKα2 KO mouse hearts, only AMPKα1
activity was present and increased during ischemia. As shown in
Fig. 2, normoxic perfusion with insulin increased PKB/Akt activity ap-
proximately 10-fold in hearts from both WT and AMPKα2 KO mice.
This insulin-mediated PKB/Akt activation was signiﬁcantly reduced
after 10 min of no-ﬂow ischemia in WT mouse hearts. We previously
showed that such PKB/Akt inhibition results from a decrease in intracel-
lular pH that occurs during an ischemic episode [11]. In agreementwith
this previous work, ischemia-dependent PKB/Akt inhibition was unaf-
fected by deletion of AMPKα2 (Fig. 2).
Next, we evaluated the effect of ischemia on p70S6K activity and
phosphorylation state. InWTmouse hearts, as for PKB/Akt, p70S6Kactiv-
ity was low in the absence of insulin and tended to decrease during is-
chemia (Fig. 3A). More importantly, insulin markedly activated p70S6K
and myocardial ischemia abolished this insulin-induced p70S6K activa-
tion (Fig. 3B), in agreement with previous data obtained in rat hearts
[11]. In line with acidosis-mediated inhibition of PKB/Akt, but contraryIschemia
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signaling during ischemia, this p70S6K inhibition was unaltered by the
deletion of the AMPKα2 isoform (Fig. 3A, B). Similarly, p70S6K phos-
phorylation on Thr389, the residue phosphorylated by mTOR down-
stream of PKB/Akt and known to correlate with p70S6K activity was
increased by insulin in bothWT andAMPKα2 KO hearts andwas equally
abolished by ischemia in both types of mice (Fig. 3C). The same results
were obtainedwhen phosphorylation of the p70S6K downstream target,
ribosomal protein S6, was measured (Fig. 3D). All these results suggest
that acidosis play the main role in p70S6K pathway inhibition during is-
chemia, AMPK being superﬂuous. To further conﬁrm the dominant role
of acidosis in the ischemia-mediated inhibition of p70S6K, we used
isolated adult rat cardiomyocytes incubated at various pH and we
compared the inhibition of the insulin-dependent phosphorylation of
PKB/Akt and p70S6K (Fig. 4). pH is known to reach value around6during
ischemia [11].We used such pH values in our in vitro study. Acidosis had
no inﬂuence on AMPK phosphorylation. In contrast, decreasing pH
progressively inhibited the insulin-mediated phosphorylation of both
PKB/Akt and p70S6K. Similarly to what happened during ischemia
(Figs. 2 and 3), the effect of acidosis was more pronounced on p70S6K
for which phosphorylation is signiﬁcantly reduced at pH 6.5 whereas
pH 6.25 was needed to affect PKB phosphorylation. Finally, we analyzed
the effect of acidosis on PKB/Akt and p70S6K phosphorylation in car-
diomyocytes isolated from adult WT and AMPKα2 KO mice (Fig. 5).
As for rat cardiomyocytes, acidosis signiﬁcantly inhibited the insulin-
dependent phosphorylation of both PKB/Akt and p70S6K in cardio-
myocytes fromWTmice. Importantly, this inhibitionwas not prevented
by the absence of the AMPKα2 isoform. These results demonstrate that
the ischemic acidosis is sufﬁcient to induce p70S6K inhibition, the con-
comitant AMPK activation being unnecessary.
Even though AMPKα2 deletion did not impair the ischemia-
mediated inhibition of p70S6K, its absence caused an interesting in-
crease in insulin response under normoxic conditions. Indeed, p70S6K
activation, its phosphorylation on Thr389 as well as the phosphoryla-
tion of ribosomal protein S6 were signiﬁcantly higher in insulin-
treated AMPKα2KOmouse hearts comparedwithWTmice (Fig. 3B–D).
3.3. Effects of insulin and ischemia on mTOR and Raptor phosphorylation
To understand the different impact of AMPKα2 deletion on p70S6K
signaling under ischemia and insulin treatment, we analyzed twoelements of themTORC1 complex, namelymTOR and Raptor phosphor-
ylation. Insulin is known to induce an 80% increase in mTOR phosphor-
ylation on Ser2448 in perfused mouse hearts [40–43]. This mTOR
Ser2448 phosphorylation has been reported to correlate with mTORC1
activation [40–43]. Here, we demonstrated that both basal (Fig. 6A)
and insulin-induced mTOR Ser2448 phosphorylation were decreased
by ischemia in WT mouse hearts (Fig. 6B). As for PKB/Akt and p70S6K,
located upstream and downstream of mTOR, respectively, the absence
of AMPKα2 did not affect mTOR inhibition suggesting, once again, a
major role of acidosis in the ischemia-mediated inhibition of the PKB/
Akt-p70S6K pathway. This is further conﬁrmed by the fact that the
insulin-mediated mTOR phosphorylation was similarly inhibited by ac-
idosis in cardiomyocytes in suspension (Fig. 4E).
One proposed target of AMPK in the negative regulation of mTOR ki-
nase activity is Raptor [28]. Ischemia increased the phosphorylation of
Raptor on its inhibitory site Ser792 in WT hearts (Fig. 6C). This effect
was greatly reduced in the presence of insulin (p = 0.17 vs. normoxia)
(Fig. 6D).More importantly and in agreementwith the data obtained on
mTOR and p70S6K, Raptor phosphorylation reached under ischemic
conditionwas clearly AMPKα2-independent (Fig. 6C, D). Similarly, Rap-
tor phosphorylationwas notmodiﬁed by acidosis (Data not shown). On
the other hand, the absence of AMPKα2 signiﬁcantly reduced Raptor
phosphorylation in normoxic hearts submitted to insulin treatment
(Fig. 6D). This decrease in phosphorylation of Raptor could explain the
increase in p70S6K activity found under the same condition.3.4. Effects of insulin and ischemia on 4E-BP1
4E-BP1 is another target of mTOR signaling in the translation ma-
chinery. As mentioned earlier, mTOR-mediated phosphorylation pro-
motes the dissociation of 4E-BP1 from eIF-4E, thereby relieving its
inhibitory action on eIF-4E, allowing protein synthesis initiation to pro-
ceed. The amount of 4E-BP1 bound to eIF-4E is considered to be inverse-
ly proportional to the protein synthesis initiation rate [44,45]. Insulin
decreased 4E-BP1/eIF-4E association by 60% under normoxic conditions
in WT mouse hearts (Fig. 7). In contrast with the effect of insulin on
p70S6K and Raptor, the insulin-induced 4E-BP1/eIF-4E dissociation
was similar in hearts from WT and AMPKα2 KO mice. On the other
hand, the insulin-mediated 4E-BP1/eIF-4E dissociation was equally
prevented by ischemia in WT and AMPKα2 KO hearts. This is similar to
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hibition of PKB/Akt, mTOR, Raptor and p70S6K.4. Discussion
The main ﬁndings of our study are the followings: (i) AMPKα2 is
required for eEF2 phosphorylation during ischemia; (ii) the inhibitory
effects of ischemia on PKB, p70S6K, mTOR and 4EBP1 were indepen-
dent of AMPKα2, acidosis playing probably the main role in these in-
hibitions; and (iii) in normoxic hearts, the absence of AMPKα2
enhanced the effects of insulin on p70S6K and Raptor. These points
are discussed below.4.1. AMPKα2 participates in eEF2 phosphorylation during myocardial
ischemia
Our previous studies on isolated rat cardiomyocytes revealed that
myocardial protein synthesis was inhibited in the absence of oxygen
[10]. Although it is well known that protein synthesis initiation is
mainly regulated by the mTOR–p70S6K pathway, this pathway is un-
likely involved in the inhibition of protein synthesis by anoxia in the
absence of anabolic stimuli such as insulin, because its activity in the
heart is minimal and cannot be signiﬁcantly inhibited further by
ischemia or anoxia [46] or by rapamycin treatment [10]. Control of
the elongation step by eEF2 phosphorylation offers an alternative ex-
planation for the hypoxia-induced inhibition of protein synthesis in
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for AMPK activation. Panel A illustrates AMPK, PKB/Akt, p70S6K and mTOR phosphorylation in control- and insulin-treated cardiomyocytes. Panels B–E show quantiﬁcation by den-
sitometric scanning of all immunoblots. The values are the means ± S.E.M. of 4 or 5 independent experiments. *P b 0.05 vs. respective unstimulated condition. #P b 0.05 vs.
insulin-treated cells at pH 7.
785B. Demeulder et al. / Biochimica et Biophysica Acta 1832 (2013) 780–790the absence of anabolic stimuli [10,12,22,25]. eEF2 is indeed phos-
phorylated at the inactivating Thr56 site during ischemia, indepen-
dently of mTOR [10,12]. Moreover, inhibition of protein synthesis
and phosphorylation of eEF2 on Thr56 during ischemia correlates lin-
early with increased AMPK activity [10,12,22,25,47]. Based on these
observations, it has been hypothesized that AMPK activation during
ischemia was responsible for the ischemia-induced inhibition of pro-
tein synthesis via the phosphorylation-induced inactivation of eEF2.
Two independent studies indicated that eEF2K, the dedicated kinase
for eEF2, could be phosphorylated and activated by AMPK further
substantiating this hypothesis [10,24]. However, a link between car-
diac AMPK and eEF2 phosphorylation was never clearly established.
We show here that eEF2 phosphorylation is markedly reduced in
hearts from AMPKα2 KO mice during ischemia (Fig. 1). Inasmuch asprotein elongation consumes four ATP equivalents per amino acid
residue incorporated into protein, the decrease in eEF2 inhibition
could contribute to the massive ATP depletion, the subsequent severe
ischemic contracture and the delayed post-ischemic contractile re-
covery that characterized the heart of AMPKα2 KO mice submitted
to ischemia [33,34]. As far as we know, this is the ﬁrst genetic evi-
dence that eEF2 phosphorylation is mainly controlled by AMPK, and
even more precisely by AMPKα2, in the ischemic adult heart
(Fig. 8). It should nevertheless be emphasized that the reduction in
eEF2 phosphorylation in AMPKα2 KO ischemic hearts was not com-
plete, which could have been due to the presence of the remaining
AMPKα1 isoform or to an AMPK independent mechanism, such as
changes in intracellular calcium known to affect eEF2K activity [10].
It has been also previously shown that eEF2K can be activated by
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phosphorylation in cardiomyocytes in suspension (data not shown)
ruling out a major role of acidosis in the regulation of this protein.
4.2. AMPKα2 is not required for ischemia-induced inhibition of the PKB/
Akt–mTOR–p70S6K–4E-BP1 pathway
Both intracellular acidosis [11] and AMPK activation [15] occur
during myocardial ischemia and both are known to negatively regu-
late the mTOR–p70S6K–4E-BP1 pathway. However, it is not clear
which of these two concomitant events plays the major role in
inhibiting this pathway during myocardial ischemia. As stated
above, mTOR–p70S6K–4E-BP1 signaling was stimulated by insulin
prior to inducing ischemia in order to investigate its inhibition. Be-
cause activation of the mTOR–p70S6K pathway requires activation
of PKB/Akt, we ﬁrst focused our attention on PKB/Akt activity. We
conﬁrmed that, in isolated mouse hearts like in perfused rat hearts
[11], insulin-induced PKB/Akt activation is inhibited by ischemia
(Fig. 2). In this previous study, we ruled out any contribution of
AMPK in this process by showing the diverging effects of ischemia
and anoxia on AMPK and PKB/Akt activities. Indeed, both ischemia
and anoxia were able to activate AMPK, but only ischemia decreased
the insulin-induced PKB/Akt activation [11]. In the same study, we
demonstrated that PKB/Akt inhibition correlated to inhibition of the
tyrosine kinase activity of the insulin receptor induced by acidosis
[11]. The present study supports our previous conclusions by showing
that the ischemia-induced inhibition of PKB/Akt activity is similar in
WT and AMPKα2 KO hearts (Fig. 8).
We next turned our attention to the downstream elements of
mTORC1 signaling, including mTOR, p70S6K, S6 and 4E-BP1. Our data
clearly indicate that deletion of AMPKα2 did not alter the inhibitory effect
of ischemia on the phosphorylation ofmTOR, Raptor and S6, on the phos-
phorylation and activation of p70S6K or on eIF-4E release from the
4E-BP1/eIF-4E complex. This rules out any possible involvement of
AMPKα2 in ischemia-induced inhibition of the mTOR–p70S6K–4E-BP1
pathway (Fig. 8). We suggest that this AMPKα2-independent inhibition
of mTOR pathway can simply result from acidosis and its subsequent in-
hibition of PKB/Akt. This hypothesis is re-enforced by the fact that acidosis
is sufﬁcient to abolish the insulin-mediatedmTOR and p70S6K activation
in cardiomyocytes, mimicking ischemia. So, even if pharmacological acti-
vation of AMPK has been linked to mTORC1 inhibition in skeletal or car-
diac myocytes [25,27,31,49], this mechanism does not seem to hold formTORC1 inhibition during myocardial ischemia. We cannot totally ex-
clude the possibility that the remaining AMPKα1 compensates for the
lack of AMPKα2. Nevertheless, several reasons advocate against this com-
pensation. Firstly and in contrast to the situation in muscles of AMPKα2
KO mice, where a 200–300% increase in AMPKα1 protein levels has
been reported [50], we previously demonstrated that AMPKα1 is neither
over-expressed nor over-activated by ischemia in AMPKα2 KO hearts
[33]. Secondly, deletion of AMPKα2 in heart impairs the regulation of
all knownAMPKmolecular andmetabolic targets studied so far including
eEF2 (the present study), acetyl-CoA carboxylase [33,51], glycolysis [33],
glucose uptake [34] and hypertrophy [36]. Thirdly, the lack of AMPKα2
clearly alters Raptor phosphorylation and p70S6K activity under
normoxic conditions (see below). This indicates that the mTORC1 path-
way is an in vivo target of AMPKα2 in the heart and that AMPKα1 cannot
compensate for its absence. Nevertheless, the generation of a cardiac-
speciﬁc double deletion of AMPKα1 and AMPKα2 would be one way to
clarify the exact role of both subunits. Moreover, it would be of interest
to determinewhether theAMPKα2 andα1 isoformshavedistinct targets,
function or localization under normoxic and ischemic conditions.
4.3. AMPKα2 attenuates activation of the p70S6K-S6 pathway under
normoxic conditions
Although AMPKα2 does not participate into the inhibition of the
mTOR–p70S6K pathway during myocardial ischemia, our data show
that it clearly controls p70S6K activity in the normoxic heart (Fig. 8). In-
deed, a 40% increase in p70S6K activity was observed in insulin-treated
AMPKα2 KOhearts.Moreover, p70S6K over-phosphorylationwas sufﬁ-
cient to likewise increase ribosomal protein S6 phosphorylation. One
might wonder if this over-activation found in the simpliﬁed model of
the perfused heart treated with a supraphysiological dose of insulin
could occur in vivo. In fact, a similar p70S6K over-activation was
found in heart extracts from fed AMPKα2 KO mice [36]. Moreover, an
analogous scenario induced by AMPK deletion was seen in skeletal
muscle where expression of a constitutively active form of PKB/Akt in
muscle increased p70S6K phosphorylation twice as high in AMPK par-
tially deleted mice compared with WT mice [52].
We went further and evaluated the phosphorylation state of
mTOR and Raptor with the aim of identifying the molecular mecha-
nism involved in p70S6K over-activation under normoxic conditions
(Fig. 8). Over-activation of p70S6K was concomitant with similar di-
rectional changes in Thr389 phosphorylation, known to be mediated
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787B. Demeulder et al. / Biochimica et Biophysica Acta 1832 (2013) 780–790by mTORC1. However, the deletion of AMPKα2 did not increase
mTOR Ser2448 phosphorylation. The Ser2448 site is associated with
PKB/Akt-TSC2-mediated activation of mTOR [40], therefore the target
of AMPKα2 should be located downstream of the PKB/Akt-TSC2 axis
and might be one of the partners of mTOR in mTORC1. Our results in-
dicate that Raptor could be this target (Fig. 8). Indeed we observed a
decreased phosphorylation of Raptor on Ser792. This site is phos-
phorylated by AMPK and leads to 14-3-3 binding and inhibition of
mTOR kinase activity [28].
p70S6K over-activation seen in AMPKα2 KO mouse heart seems,
at ﬁrst sight, inconsistent with the lack of phenotypic modiﬁcations
in these hearts under basal conditions [36]. We postulate that themodest p70S6K over-activation found in the AMPKα2 KO genetic
model is insufﬁcient to induce hypertrophy under basal conditions.
Thus, a considerable increase in p70S6K activity, as in transgenic mice
overexpressing p70S6K (resulting in a 7- to 11-fold increase in p70S6K
activity), would lead to mild hypertrophy [53]. On the other hand, it is
known that heart size results from complex interactions between the
regulation of protein synthesis, protein degradation and gene expres-
sion. AMPK could thus negatively modulate other factors regulating
heart size thereby counteracting the over-activated p70S6K effect. This
could explain the fact that LKB1 (one of upstream kinases for AMPK)
KO mice [54] and transgenic mice overexpressing a dominant negative
form of AMPK [55]were characterized by a smaller heart size.Whatever
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heart under basal conditions, p70S6K over-phosphorylation could cer-
tainly participate in the more rapid onset of myocardial hypertrophy
seen when these mice were submitted to pro-hypertrophic treatments
such as isoproterenol injection [36] and transaortic constriction [51].
Curiously, 4E-BP1, the other downstream target of mTORC1, was
not affected by deletion of AMPKα2 under normoxic conditions.Insulin
PKB
mTOR
Raptor
p70S6K 4E-BP1
S6 
p70S6
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Basal 
AMPK 2
NORMOXIC HEART
Fig. 8. Proposed model for the regulation of heart eEF2 and mTORC1/p70S6K pathways b
AMPKα2 activity negatively regulates the mTOR partner Raptor. This partial inhibition pr
not participate in the ischemia-dependent inhibition of the PKB/mTOR/p70S6K/S6/4E-BP1
mainly explains this inhibition. On the other hand, ischemia-dependent activation of AMPKα
ever, the participation of other mechanisms (dashed lines), including AMPKα1, cannot be to
pH, IR, insulin receptor.This suggests that p70S6K and 4E-BP1 could be differently regulated.
Our results conﬁrm the study of Wang and co-workers [45] who
showed that the outputs frommTORC1 to 4E-BP1 and p70S6K are clear-
ly distinct, even if both 4E-BP1 and p70S6K bind Raptor. It has also been
shown more recently that incubation of rat muscles with leucine in-
duced stimulation of the mTOR-p70S6K pathway via a decrease in
AMPK activity while 4E-BP1 phosphorylation was unaffected [56].Insulin
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2 is the main mechanism leading to phosphorylation-induced inhibition of eEF2. How-
tally ruled out. See Discussion section for more details. Abbreviations: pHi, intracellular
789B. Demeulder et al. / Biochimica et Biophysica Acta 1832 (2013) 780–790Although speculative, it is possible that AMPK interacts with Raptor in
such a way that only p70S6K activation is perturbed. 4E-BP1 was not
the sole regulator of protein synthesis to be unaffected by deletion of
AMPKα2. Indeed, we also evaluated the phosphorylation state of two
other components located downstream of PKB/Akt parallel with the
mTOR pathway, namely glycogen synthase kinase-3 (GSK-3) and its
substrate, eukaryotic initiation factor 2B (eIF2B) (data not shown). Nei-
ther GSK3 nor eIF2B phosphorylation was altered in hearts of AMPKα2
KOmice submitted to insulin and/or ischemic conditions. The fact that,
among all the factors regulating protein synthesis, only p70S6K is al-
tered inmice lacking AMPKα2 could also explain the absence of a cardi-
ac phenotype under basal conditions.
4.4. Limitations of the study
Our study was performed with glucose as the sole energy providing
substrate. We deliberately perfused hearts without fatty acids to avoid
any possible interference with insulin and ischemia signaling. It would
nonetheless be interesting to compare our results with those of similar
studies performed in vivo under more physiological conditions.
5. Conclusions
The present work shows that the AMPKα2 isoform (i) puts a brake
on p70S6K-ribosomal protein S6 signaling under normoxic conditions,
probably by acting on Raptor phosphorylation; (ii) is involved in the
regulation of eEF2 phosphorylation during an ischemic episode;
but (iii) is not required for the inhibition of the PKB/Akt–mTORC1–
p70S6K–4E-BP1 pathway during myocardial ischemia. Our study pro-
vides the ﬁrst genetic evidence in perfused hearts of a speciﬁc role for
one of the two AMPK catalytic α-subunits in the control of signaling
pathways that impact on protein synthesis in (patho)-physiological
cardiac models. The work also questions the generally accepted notion
that mTORC1–p70S6K signaling is inhibited by cardiac ischemia via an
AMPK-dependent mechanism.
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